Bibliographic Details
| Title: |
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. |
| Authors: |
Monjazeb, Arta M., Daly, Megan E., Luxardi, Guillaume, Maverakis, Emanual, Merleev, Alexander A., Marusina, Alina I., Borowsky, Alexander, Mirhadi, Amin, Shiao, Stephen L., Beckett, Laurel, Chen, Shuai, Eastham, David, Li, Tianhong, Vick, Logan V., McGee, Heather M., Lara, Frances, Garcia, Leslie, Morris, Leigh Anne, Canter, Robert J., Riess, Jonathan W. |
| Source: |
Nature Communications; 9/2/2023, Vol. 14 Issue 1, p1-14, 14p |
| Subject Terms: |
STEREOTACTIC radiotherapy, NON-small-cell lung carcinoma, ATEZOLIZUMAB, T cells, CLINICAL trials |
| Abstract: |
Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addition of the immune-checkpoint-inhibitor (ICI) atezolizumab to standard-of-care SABR can improve outcomes. We initiated a multi-institutional single-arm phase I study (NCT02599454) enrolling twenty patients with the primary endpoint of maximum tolerated dose (MTD); secondary endpoints of safety and efficacy; and exploratory mechanistic correlatives. Treatment is well tolerated and full dose atezolizumab (1200 mg) is the MTD. Efficacy signals include early responses (after 2 cycles of ICI, before initiation of SABR) in 17% of patients. Biomarkers of functional adaptive immunity, including T cell activation in the tumor and response to ex-vivo stimulation by circulating T cells, are highly predictive of benefit. These results require validation and are being tested in a phase III randomized trial. Stereotactic ablative radiotherapy (SABR) is standard-of-care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), however the risk of systemic recurrences remains high. Here the authors report the results of a phase I study testing the addition of atezolizumab (anti-PD-L1) to SABR in high risk, medically inoperable, early-stage, NSCLC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
